Everett Thomas R, Wilkinson Ian B, Lees Christoph C
Department of Fetal Medicine, Box 228, The Rosie Hospital, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB2 2SW United Kingdom.
J Matern Fetal Neonatal Med. 2012 Jan;25(1):50-2. doi: 10.3109/14767058.2011.557791. Epub 2011 Mar 10.
Drug development in pregnancy and particularly in preeclampsia has been long neglected. Preeclampsia is a leading cause of maternal mortality, and early-onset preeclampsia can result in serious long-lasting consequences to the neonate. Many treatments have been trialed with varying success including vitamin supplementation, low-molecular-weight heparins, and aspirin. In this commentary, we particularly focus on the current status of drugs in development specifically aimed at preeclampsia. We outline the current understanding of the causes of the endothelial dysfunction seen in preeclampsia and, as such, potential therapeutic targets. With treatment of preeclampsia being largely unchanged in decades, there is an urgent need for novel therapies particularly those directed at the underlying causes that may allow for extremely preterm delivery, and its myriad consequences, to be avoided.
孕期尤其是子痫前期的药物研发长期以来一直被忽视。子痫前期是孕产妇死亡的主要原因，早发型子痫前期会给新生儿带来严重的长期后果。许多治疗方法都曾进行过试验，但效果各异，包括维生素补充、低分子量肝素和阿司匹林。在这篇评论中，我们特别关注专门针对子痫前期的正在研发的药物的现状。我们概述了目前对子痫前期所见内皮功能障碍病因的理解，以及潜在的治疗靶点。由于子痫前期的治疗在几十年里基本没有变化，迫切需要新的疗法，尤其是那些针对潜在病因的疗法，这可能有助于避免极早产及其带来的诸多后果。
